Ponatinib (PON) in patients (pts) with Philadelphia chromosome-positive (Ph plus ) leukemias resistant or intolerant to dasatinib or nilotinib, or with the T315I mutation: Longer-term follow up of the PACE trial.

被引：5

作者：

Kantarjian, Hagop M.

Kim, Dong-Wook

Pinilla-Ibaz, Javier

Le Coutre, Philipp D.

Paquette, Ronald

Chuah, Charles

Nicolini, Franck E.

Apperley, Jane

Khoury, Hanna Jean

Talpaz, Moshe

DiPersio, John F.

Baccarani, Michele

Lustgarten, Stephanie

Haluska, Frank G.

Guilhot, Francois

Deininger, Michael W. N.

Hochhaus, Andreas

Hughes, Timothy P.

Shah, Neil P.

Cortes, Jorge E.

机构：

[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[2] Catholic Univ Korea, Seoul St Marys Hosp, Seoul, South Korea

[3] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA

[4] Charite, Campus Virchow Klinikum, D-13353 Berlin, Germany

[5] Univ Calif Los Angeles, Ronald Reagan UCLA Med Ctr, Los Angeles, CA USA

[6] Duke NUS Grad Med Sch, Singapore Gen Hosp, Singapore, Singapore

[7] Ctr Hosp Lyon Sud, Pierre Benite, France

[8] Univ London Imperial Coll Sci Technol & Med, Ctr Haematol, London, England

[9] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA

[10] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA

[11] Washington Univ, Sch Med, St Louis, MO USA

[12] S Orsola Malpighi Univ Hosp, Dept Hematol Oncol L&A Seragnoli, Bologna, Italy

[13] ARIAD Pharmaceut Inc, Cambridge, MA USA

[14] Ctr Hosp Univ Poitiers, Poitiers, France

[15] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA

[16] Univ Klinikum Jena, Jena, Germany

[17] SA Pathol, Adelaide, SA, Australia

[18] Univ Adelaide, SAHMRI, Adelaide, SA, Australia

[19] Univ Calif San Francisco, San Francisco, CA 94143 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期

关键词：

D O I：

10.1200/jco.2014.32.15_suppl.7081

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

7081

引用

页数：1

共 32 条

[1] PONATINIB IN PATIENTS (PTS) WITH PHILADELPHIA CHROMOSOME- POSITIVE (PH plus ) LEUKEMIAS RESISTANT OR INTOLERANT TO DASATINIB OR NILOTINIB, OR WITH THE T315I MUTATION: LONGER-TERM FOLLOW-UP OF THE PACE TRIAL
le Coutre, P. D.
Kim, D. W.
Pinilla-Ibarz, J.
Paquette, R.
Chuah, C.
Nicolini, F. E.
Apperley, J. F.
Khoury, H. J.
Talpaz, M.
DiPersio, J. F.
DeAngelo, D.
Abruzzese, E.
Rea, D.
Baccarani, M.
Muller, M.
Gambacorti-Passerini, C.
Lustgarten, S.
Haluska, F. G.
Guilhot, F.
Deininger, M. W.
Hochhaus, A.
Hughes, T. P.
Shah, N. P.
Kantarjian, H. M.
Cortes, J. E.
HAEMATOLOGICA, 2014, 99 : 334 - 334
[2] Longer-term follow up of a phase I study of ponatinib in patients (pts) with Philadelphia chromosome-positive (Ph plus ) leukemias.
Talpaz, Moshe
Cortes, Jorge E.
Kantarjian, Hagop M.
Shah, Neil P.
Bixby, Dale L.
Flinn, Ian
O'Hare, Thomas
Hu, Simin
Rivera, Victor M.
Clackson, Tim
Turner, Christopher D.
Haluska, Frank G.
Drucker, Brian J.
Deininger, Michael W. N.
Mauro, Michael J.
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[3] LONGER-TERM FOLLOW-UP OF A PHASE 1 STUDY OF PONATINIB IN PATIENTS (PTS) WITH PHILADELPHIA CHROMOSOME-POSITIVE (PH plus ) LEUKEMIAS
Cortes, J.
Talpaz, M.
Kantarjian, H. M.
Shah, N. P.
Bixby, D.
Flinn, I. W.
O'Hare, T.
Hu, S.
Rivera, V.
Clackson, T.
Turner, C.
Haluska, F.
Druker, B. J.
Deininger, M. W.
Mauro, M. J.
HAEMATOLOGICA, 2014, 99 : 335 - 335
[4] PACE: A PIVOTAL PHASE 2 TRIAL OF PONATINIB IN PATIENTS WITH CML AND PH plus ALL RESISTANT OR INTOLERANT TO DASATINIB OR NILOTINIB, OR WITH THE T315I MUTATION
Cortes, J.
Kim, D. W.
Pinilla, J.
Paquette, R.
Le Coutre, P.
Chuah, C.
Nicolini, F.
Apperley, J.
Khoury, J.
Talpaz, M.
DiPersio, J.
D'Angelo, D.
Rea, D.
Abruzzese, E.
Mueller, M.
Baccarani, M.
Gambacorti-Passerini, C.
Christopher, C.
Haluska, F.
Kantarjian, H.
HAEMATOLOGICA, 2012, 97 : 453 - 453
[5] Ponatinib In Patients (pts) With Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph plus ALL) Resistant Or Intolerant To Dasatinib Or Nilotinib, Or With The T315I BCR-ABL Mutation: 2-Year Follow-Up Of The PACE Trial
Cortes, Jorge E.
Kim, Dong-Wook
Pinilla-Ibarz, Javier
le Coutre, Philipp D.
Paquette, Ronald
Chuah, Charles
Nicolini, Franck E.
Apperley, Jane F.
Khoury, H. Jean
Talpaz, Moshe
DiPersio, John F.
DeAngelo, Daniel J.
Abruzzese, Elisabetta
Rea, Delphine
Baccarani, Michele
Mueller, Martin C.
Gambacorti-Passerini, Carlo
Lustgarten, Stephanie
Rivera, Victor M.
Clackson, Tim
Turner, Christopher D.
Haluska, Frank G.
Guilhot, Francois
Deininger, Michael W.
Hochhaus, Andreas
Hughes, Timothy P.
Goldman, John M.
Shah, Neil P.
Kantarjian, Hagop M.
BLOOD, 2013, 122 (21)
[6] PACE: A pivotal phase II trial of ponatinib in patients with CML and Ph plus ALL resistant or intolerant to dasatinib or nilotinib, or with the T315I mutation.
Cortes, Jorge E.
Kim, Dong-Wook
Pinilla-Ibarz, Javier
Paquette, Ronald
le Coutre, Philipp D.
Chuah, Charles
Nicolini, Franck E.
Apperley, Jane
Khoury, Hanna Jean
Talpaz, Moshe
DiPersio, John F.
DeAngelo, Daniel J.
Rea, Delphine
Abruzzese, Elisabetta
Mueller, Martin C.
Baccarani, Michele
Gambacorti-Passerini, Carlo
Turner, Christopher D.
Haluska, Frank G.
Kantarjian, Hagop
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[7] A Pivotal Phase 2 Trial of Ponatinib in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph plus ALL) Resistant or Intolerant to Dasatinib or Nilotinib, or with the T315I BCR-ABL Mutation: 12-Month Follow-up of the PACE Trial
Cortes, Jorge E.
Kim, Dong-Wook
Pinilla-Ibarz, Javier
le Coutre, Philipp
Paquette, Ron
Chuah, Charles
Nicolini, Franck E.
Apperley, Jane
Khoury, H. Jean
Talpaz, Moshe
DiPersio, John F.
DeAngelo, Daniel J.
Abruzzese, Elisabetta
Rea, Delphine
Baccarani, Michele
Muller, Martin C.
Gambacorti-Passerini, Carlo
Wong, Stephane
Lustgarten, Stephanie
Rivera, Victor M.
Clarkson, Tim
Turner, Christopher D.
Haluska, Frank G.
Guilhot, Francois
Deininger, Michael W.
Hochhaus, Andreas
Hughes, Timothy
Goldman, John M.
Shah, Neil
Kantarjian, Hagop M.
BLOOD, 2012, 120 (21)
[8] Long-Term Follow-up of the Efficacy and Safety of Ponatinib in Philadelphia Chromosome-Positive Leukemia Patients with the T315I Mutation
Jabbour, Elias J.
Cortes, Jorge E.
Talpaz, Moshe
Baccarani, Michele
Mauro, Michael J.
Hochhaus, Andreas
Hughes, Timothy P.
Guilhot, Francois
Deininger, Michael W.
Shah, Neil
Bixby, Dale L.
Flinn, Ian W.
O'Hare, Thomas
Lustgarten, Stephanie
Rivera, Victor M.
Santillana, Sergio
Kantarjian, Hagop M.
BLOOD, 2016, 128 (22)
[9] Initial Findings From the PACE Trial: A Pivotal Phase 2 Study of Ponatinib in Patients with CML and Ph+ ALL Resistant or Intolerant to Dasatinib or Nilotinib, or with the T315I Mutation
Cortes, Jorge E.
Kim, Dong-Wook
Pinilla-Ibarz, Javier
Le Coutre, Philipp D.
Chuah, Charles
Nicolini, Franck E.
Paquette, Ron
Apperley, Jane F.
DiPersio, John F.
Khoury, H. Jean
Rea, Delphine
Talpaz, Moshe
DeAngelo, Daniel J.
Abruzzese, Elisabetta
Baccarani, Michele
Mueller, Martin C.
Gambacorti-Passerini, Carlo
Wong, Stephane
Lustgarten, Stephanie
Turner, Christopher D.
Rivera, Victor M.
Clackson, Tim
Haluska, Frank
Kantarjian, Hagop M.
BLOOD, 2011, 118 (21) : 52 - 53
[10] Overall Survival With Ponatinib Versus Allogeneic Stem Cell Transplantation in Philadelphia Chromosome-Positive Leukemias With the T315I Mutation
Nicolini, Franck E.
Basak, Grzegorz W.
Kim, Dong-Wook
Olavarria, Eduardo
Pinilla-Ibarz, Javier
Apperley, Jane F.
Hughes, Timothy
Niederwieser, Dietger
Mauro, Michael J.
Chuah, Charles
Hochhaus, Andreas
Martinelli, Giovanni
DerSarkissian, Maral
Duh, Mei Sheng
McGarry, Lisa J.
Kantarjian, Hagop M.
Cortes, Jorge E.
CANCER, 2017, 123 (15) : 2875 - 2880

← 1 2 3 4 →